Title: Preliminary results from a First-in-Human (FIH), open-label Phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab. Session Type: Poster Session Abstract Number: 8631 Date and Time: June 3, 2024, 1:30 PM – 4:30 PM (CDT) Key observations from the study include: With these encouraging early results, it is important to note that the study remains ongoing. Further data will become available and analyzed through the next few months to gain a deeper unders ...